Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Omeza Holdings Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The actions involve 2 examiners and 2 art units, indicating separate examination channels.
ROZOF, TIMOTHY R is the listed busiest examiner, with 1 pending matter. Counsel should manage the matters independently while maintaining consistent positions where the underlying technology and claim strategy overlap.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.3% |
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18495265 | COMPOSITION OF AND METHOD FOR TREATING INJURY AND/OR SKIN CONDITIONS | SOROUSH, LAYLA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18920409 | TOPICAL COMPOSITIONS FOR REDUCING SCARRING | ROZOF, TIMOTHY R | — |
| 18495265 | COMPOSITION OF AND METHOD FOR TREATING INJURY AND/OR SKIN CONDITIONS | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18920409 | TOPICAL COMPOSITIONS FOR REDUCING SCARRING | ROZOF, TIMOTHY R | 1625 | §102DP | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18495265 | COMPOSITION OF AND METHOD FOR TREATING INJURY AND/OR SKIN CONDITIONS | SOROUSH, LAYLA | 1622 | §103§112Other | Non-Final OA | — | Pending | Oct 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOmeza Holdings Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Timothy R Rozof has the most, with 1 of Omeza Holdings Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
